The local company announced Friday morning at 5:35 a.m. that it was withdrawing its bid to buy Evotec for about $11.52 per ...

As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

Evotec (EVO) announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the company effective December 31. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery ...

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its ...

HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig ...

Halozyme Therapeutics (HALO) stock gains as company withdraws proposal to acquire Evotec SE (EVO), citing latter's reluctance ...

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding ...

Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...